May 11, 2021
Vancouver, British Columbia–(Newsfile Corp. – May 11, 2021) – Entheon Biomedical Corp. (CSE: ENBI) today announced that, Timothy Ko, CEO of Entheon, will be attending the Q2 Virtual Investor Summit.
|Event||Q2 Investor Summit|
|Date||May 17-18th, 2021|
|Presentation||May 17th at 10:15 AM ET|
About Entheon Biomedical Corp.
Entheon Biomedical is a drug development and biotechnology company whose primary aim is to provide solutions for people battling addiction so they can reclaim their lives and potential. With a focus on advancing the therapeutic potential of the DMT molecule through clinical trials and a traditional regulatory framework, Entheon is also developing specialized tools to personalize care, from patient assessment to psychedelic treatment and beyond. Entheon believes a comprehensive and holistic approach to care will significantly increases the odds of permanent recovery for those struggling with addiction disorders.